|
|
991 Highway 22, suite 200A
Bridgewater, NJ 08807 USA
phone:908-998-1340
fax:908-864-8957
|
|
| Symbol |
Private |
| Founded |
2004 |
| Employees |
8 |
|
|
| www.neurotez.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Developing therapeutic manipulation technologies to treat Alzheimer's. |
|
| Management |
| Nikolaos Tezapsidis, PhD, President & CEO; Mark A. Smith, PhD, CSO; Jane M. Johnston, PhD, Executive Director of Research and Development; Eugene J. Oliva, MBA, Chief Financial Officer; Michael J. Hoy, M.S., Director of Regulatory Affairs. |
| |
|
|
| |
|
| Keywords |
| biochemistry, molecular, biology, biopharmaceuticals, protein, clinical development, Alzheimer's disease. |
|
|
|
| Description |
|
Neurotez Inc. is a privately held Delaware corporation formed to launch the clinical development of recombinant human Leptin as a hormone replacement therapy for Alzheimer's disease ("AD"), and as a preventative remedy for those at risk. Leptin can be considered a relatively �de-risked� drug candidate for this indication for the following reasons:
� Compelling epidemiological, in vitro, and animal model data providing evidence of both desired biomarker results and cognitive improvement.
� Substantial safety database already in existence for Leptin due to human studies completed by other companies for other therapeutic indications.
While this program has a potential for high impact in healthcare in the short term, the building of a fully-integrated company, with a platform including discovery efforts to proof of concept clinical trials is our long term aim. |
|
| Products / Services |
The most advanced product is a recombinant Leptin product for Alzheimer's diseaase.
|
|
| Market / Customers |
Alzheimer's Disease (AD) is the primary cause of cognitive impairment among the elderly (40-50% of 85 yr olds may have AD). There are currently 5.1 million people with AD in the US alone, costing over $100 billion annually and making AD the third most costly disease after heart disease and cancer. It is estimated that by the year 2050, 14 million Americans will be afflicted with AD, as the baby boomers continue to age.
|
|
| Competitors / Substitutes / Alternatives |
Currently available AD drugs provide only limited symptomatic relief without addressing the underlying pathobiology of the disease. Drug development programs seeking to address AD are underway at a significant number of Big Pharma and biopharmaceutical companies, but Neurotez is the only commercial organization known to be pursuing a Leptin-based approach. Importantly, major drug companies have demonstrated a strong willingness to enter into lucrative partnership arrangements with small, research-focused companies that have novel AD compounds.
|
|
| Status |
| -Pre-IND |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members